Bryan Johnson's Livestreamed Psilocybin Session: Can a Psychedelic Be a Longevity Therapy?

The Setup: Dose Two of Three

This was the second of three planned doses. Before taking it, Johnson said he was nervous because of how the first session went. Last time, he said, his "inhibitions were just washed away." He described the loss of the usual mental check: normally you have a thought and ask whether it is appropriate to say, and you can stop it, but deep in the mushrooms those checks weren't there. His contingency plan was simple: if he went "off the rails," he would put on a face mask and lie down.

He also compared the doses. The first was "25" and this one was "28." No unit is given for those figures in the stream. He said the larger dose was "definitely knocking me out."

Why Psilocybin, and Why Measure So Much

Dr. Carl Seager, introduced as a longevity physician who helped design the protocol, argued that "this type of experiment is kind of what needs to start happening." He pointed to what he described as preclinical studies suggesting psilocybin can reverse biological aging in human cells. Asked about the purpose of the trip, the team framed it as part of a broader search for therapies that could slow the speed of aging and reverse aging damage. They repeated that they do not know whether psilocybin will be one of those therapies and are exploring it.

The team said they were measuring 249 biomarkers and called it "the most quantified psychedelic experiment in history." Before dosing, they spent about 30 minutes on baseline measurements: saliva samples, thermal body-heat readings, blood pressure, and brain measurements with Kernel.

Ryan Fields explained Kernel, a company started seven years earlier. It took advances in lasers and consumer electronics to build what Fields called "a pulse oximeter on steroids" that measures oxygen in the brain. That lets researchers map which parts of the brain are active at a given time. Fields said this could be used to study brain health, signatures of drug interactions, or mental states. Asked for parting words before the dose, Fields said: "Good luck. I'll see you on the other side."

Weighing and Taking the Dose

The dosing itself was improvised. Johnson said he would take all of a 4.67 g portion and add another 0.56 g to reach what he called 5.3 g. On the scale, the team said they were aiming for 5.23 g. At one point they were at 4.9 g and then overshot to 5.32 g, and they debated removing a little. He took the mushrooms in a lemon mixture, remarked that it was "lemony," and added more lemon for a second round to get the remaining bits.

Talmage Joins

Johnson's son, Talmage, joined early on. Asked what it was like to watch his father take a psychedelic, Talmage joked that when people ask what his dad does, he never knows what to say. Now he could say his dad "occasionally trips balls on X in front of hundreds of thousands of people." He said he had "no trepidation" about watching, found it fun, and asked what would come next to "top it off."

Johnson spoke warmly about his son. He said Talmage is "overjoyed when I experience something that I'm happy about," that he felt lucky to be his dad, and that he was glad they were "doing life together." Talmage suggested the roles might reverse during the session, with him in a parental role and his father in a childlike one. Johnson agreed that was possible. That idea came back later in the stream.

Ashlee Vance and the Early Days of Blueprint

Journalist Ashlee Vance also joined. Johnson recalled that when he and his team first started Blueprint and began publishing online, "nobody was paying any attention." Then Vance wrote an article that "blew up." Vance said they had expected the piece to do well but couldn't have imagined how big the response would be.

Onset: "It's Hit"

Mid-conversation, Johnson announced, "I just need to say it's hit." He described thoughts reaching the front of his mind much faster and said there were "very few checks right now" on what he would say. The team told him he would peak in about another hour and a half.

His descriptions escalated. He said his body felt "nimble and supple and loose," then that the whole room was pulsating and "everything's alive." When Talmage jokingly asked whether the plants were speaking to him, he noticed they looked like they needed water. He then corrected himself: if you stuck a finger in the soil, you could tell they had been watered recently.

He also described his own mind. Normally, he said, conversation runs on autopilot. Now, when he started a conversation, he felt he had to "preload" a model of interacting with another person. He said he could feel the structure of the mind anticipating conversation and could watch that modeling happen in real time.

Later he said his whole body was vibrating and he was seeing colors everywhere. He also said speaking felt like it took away from the experience, calling speech a "lower dimensional expression" compared with the much richer sensory experience. He described the trip as pulling him inward and demanding silence. His team suggested he lie down, and he agreed.

Timing: T-max

With Johnson out of earshot, the stream moved into what one host called "the educational portion of the show." A participant addressed as Hamilton was asked whether there are typical stages at this dose. The answer used pharmacology terms. T-max is the time until psilocin reaches its highest concentration in blood plasma, and the participant said it is roughly 1.5 to 2 hours after taking psilocybin by mouth. By that measure, Johnson was nearing T-max.

A Personal Route Into Psychedelics: Ibogaine and Navy SEALs

One guest explained how they became interested in psychedelics. A family member was addicted to heroin. The guest heard about ibogaine, which they called a very potent psychedelic, on a Tim Ferriss podcast. It struck them as possibly "the only tool" that might help people get off opiates. They later hosted a dinner with a group of Navy SEALs. The guest said the SEALs described going to Mexico for a single treatment and coming back feeling "kind of cured" of PTSD, depression, addiction, or traumatic brain injury.

Moving the Question Beyond Psychiatry: Gül Dölen's Stroke Research

The same guest described work by Gül Dölen, a researcher at Berkeley. As the guest summarized it, Dölen's hypothesis is that psychedelics work by reopening "critical periods." To test it, Dölen is treating stroke patients with psilocybin to see whether they regain motor control. The guest liked this approach because it moves the conversation "out of the subjective psychiatric domain." The outcome is measurable: either patients regained motor control or they didn't.

Drug Policy: Schedule I and Reclassification

A guest outlined the legal situation in the United States. At the federal level, nearly every major psychedelic is a Schedule I controlled substance, the most restrictive schedule, which by definition says the drug has no medical value. The guest hoped medical research could gradually change that. They said that, for now, MDMA and psilocybin are the main candidates for reclassification that would let physicians prescribe them.

The guest also defended the livestream format. Showing people what the experience is like helps demystify it and shows it can be beneficial, they said. They thanked people like Johnson for "busting open the Overton window" on what can be talked about, researched, and filmed. Their hope was that experiments like this would shift the conversation away from hard-to-treat psychological disorders. The new question would be whether psilocybin can help healthy people live healthier, more productive, and more meaningful lives.

The Epigenetic Rationale

Another guest laid out the scientific rationale behind the longevity framing. They said new factors and molecules that change gene expression and cause cellular rejuvenation are being discovered "every week." In their view, epigenetic aging or dysfunction is "fundamentally and functionally" the root of all disease. As time goes on, they explained, the epigenome shifts. They cited studies, which they said they had discussed with Johnson, suggesting that some compounds in psychedelic substances change gene expression and may have rejuvenating effects.

A speaker expanded on this. They argued that DNA itself "doesn't get that damaged." The problem is the epigenome. The "magic cure" for aging, in this framing, would be molecules that could be applied to any cell to put the epigenetic marks back where they belong and make the cell young again. The speaker said a series of papers had identified compounds found in mushrooms like the ones Johnson took that "may actually have this effect," resetting the epigenome and making tissue youthful again. They presented this as a possibility, saying mushrooms "may be" a natural source of such a molecule. They did not claim it had been shown in people.

Spirituality, "Plant Medicine," and the Search for a Bridge

A guest said the other remarkable part of the experiment was the spiritual and religious dimension. They had wanted to ask Johnson about it but realized that wasn't possible given his state. Their interest was the connection between decades of meditation, religious, and spiritual practice and the science being discussed. They said people are "still trying to find those bridges." They thought Johnson might be looking for that link, while noting they would not put words in his mouth. They also said they did not believe he was doing this recreationally.

Another speaker called Johnson a "one-man FDA" who tests everything on himself, legitimizes it, and popularizes it. They hoped he would "survive for a long time" and pass on "the cheat codes." They added that there "should be a thousand Brians," even 10,000.

The same speaker argued that "plant medicines" have been with humans as long as there have been humans. They cited, somewhat loosely, psychedelic traditions in ancient cultures. They mentioned something in Greek mythology that they couldn't quite recall, possibly connected to the cult of Pythagoras, as well as soma in Indian mythology and LSD among the 1960s hippies. They said mushrooms put people into "highly natural psychospiritual states." You can reach those states through meditation, they said, but in modern life few people have time, so mushrooms work "like a cheat code." They called mushrooms "relatively harmless," especially in small amounts. They acknowledged Johnson was taking a "heroic dose" but said they didn't think it would poison him.

They ended with a speculation they labeled as such. Fungi are among the oldest living things on Earth, and humans are relatively new. So they weren't surprised that eating the fruiting body might feel like communion with nature, perhaps as a way for part of nature to communicate with us. "Obviously, very fanciful," they added.

Peak Measurements: Saliva and Reaction Time

At the peak, the team had to take measurements, and they apologized to Johnson: "You signed up for this." Seager and Fields rejoined the call. Johnson, laughing, kept losing track of whether people were still there and called them back several times. Someone explained that he couldn't see them on screen and assumed they had left.

The saliva sample was, one team member said, what they had expected to be the hardest part. Johnson struggled to produce enough, said he felt he needed to chew something, and was urged not to spill it. The team called it "liquid gold." He insisted he still had motor control. Someone joked that this was where they needed Grimes and a DJ set for encouragement. A team member noted that the same thing had happened in the previous session, where the other measurements took a long time.

Johnson also took a reaction-time test. He called one attempt "so bad" and "so long." After Fields's one-word encouragement, "Focus," he joked that Fields had wanted him to do badly. A result read out as "point four" was, he said, his worst score.

Second Peak: Connection and Family

Later Johnson appeared giddy, and the team thought he had just peaked. He said he had "outsourced the whole situation" and was "just pure experience." Having everyone there, he said, felt "like peak life."

One participant said that after the previous session they had thought a lot about how Johnson seemed "overcome by … the connectivity of everything, people, places, things." Asked about it this time, he didn't really answer the question. He said instead that it overjoyed him to have them there with him. Talmage pointed this out affectionately. He said it was like a parent talking to a small child who is somewhere else entirely, and that his father's body language made him look like a child with a glow, as if he'd just come "out the womb."

Johnson reflected on parenthood with his usual bluntness. He said kids are "so painful on so many levels" and "ruin your life on every possible layer," and also that they are "the most majestic creations in our reach." He told Talmage they had "done the hard work" in their relationship and that he saw him as a person, "no judgment, no filters." Talmage replied that his father is "the light that keeps on giving" and joked, "we even like you more on shrooms." Another participant said the experience brought out what Johnson must have been like as a boy.

Closing

The stream ended with the team thanking viewers. One member said they had gone into the session believing "we're all connected" and wanted viewers to have a good experience too, then added, laughing, "I'm high." The highlights did not include any biomarker results. The central question of whether psilocybin has measurable longevity effects was left open, pending the data from the 249 biomarkers and the remaining dose.